Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of H101 plus tislelizumab and platinum doublet chemotherapy in untreated advanced non-small cell lung cancer
ChiCTR2200061305Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Oncorine and tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: progression-free survival. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
Oncorinetislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200061305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061305.